Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

TLSI

TriSalus Life Sciences Inc

Jun 14 • 04:00PM ET

5.77

Dollar change -0.06
Percentage change -1.03	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.42	Insider Own	88.60%	Shs Outstand	26.41M	Perf Week	-11.37%
Market Cap	156.71M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	0.00%	Shs Float	3.10M	Perf Month	-38.55%
Income	-53.07M	PEG	-	EPS next Q	-0.46	Inst Own	3.42%	Short Float	13.33%	Perf Quarter	-40.70%
Sales	17.37M	P/S	9.02	EPS this Y	73.51%	Inst Trans	-0.11%	Short Ratio	8.75	Perf Half Y	-3.03%
Book/sh	-1.31	P/B	-	EPS next Y	26.90%	ROA	-265.61%	Short Interest	0.41M	Perf Year	-44.57%
Cash/sh	0.15	P/C	39.47	EPS next 5Y	-	ROE	-2.48%	52W Range	3.32 - 16.24	Perf YTD	-31.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-64.47%	Beta	0.52
Dividend TTM	-	Quick Ratio	0.71	Sales past 5Y	16.44%	Gross Margin	82.55%	52W Low	73.80%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	0.92	EPS Y/Y TTM	-242070.00%	Oper. Margin	-238.23%	RSI (14)	22.30	Volatility	7.31% 8.01%
Employees	112	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-305.50%	Recom	1.00	Target Price	14.67
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-1000.92%	Payout	-	Rel Volume	0.50	Prev Close	5.83
Sales Surprise	4.69%	EPS Surprise	-3.45%	Sales Q/Q	-	Earnings	May 15 BMO	Avg Volume	47.24K	Price	5.77
SMA20	-25.96%	SMA50	-35.51%	SMA200	-22.48%	Trades		Volume	23,706	Change	-1.03%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Canaccord Genuity	Buy	$12

Jun-03-24 07:00AM	TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting (Business Wire)
May-24-24 06:05AM	TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants (Business Wire) -20.75%
May-15-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) -7.49%
08:00AM	TriSalus Reports Q1 2024 Financial Results and Business Update (Business Wire)
May-07-24 07:00AM	TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors (Business Wire)
04:58PM	Loading…
May-06-24 04:58PM	TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call (Business Wire)
Apr-30-24 04:35PM	TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav Infusion System Growth Initiatives (Business Wire)
Apr-01-24 12:53PM	TLSI Stock Earnings: TriSalus Life Sciences Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +5.13%
09:33AM	TriSalus Life Sciences Inc (TLSI) Q4 and Full Year 2023 Earnings: Revenue Growth Amidst Late ... (GuruFocus.com)
08:00AM	TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update (Business Wire)
Mar-26-24 08:00AM	TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting (Business Wire)
Mar-21-24 08:00AM	TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting (Business Wire)
Mar-11-24 05:15PM	TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results (Business Wire)
Mar-07-24 07:00AM	TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Associations Adopted Name Council for Nelitolimod as the Nonproprietary Drug Name for SD-101 (Business Wire)
Feb-29-24 07:00AM	TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors (Business Wire)
07:00AM	Loading…
Dec-14-23 07:00AM	TriSalus Life Sciences Announces CMS Reimbursement for the TriNav Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code (Business Wire) +33.61%
Nov-14-23 12:27PM	TriSalus Life Sciences Inc Reports Revenue Growth and Clinical Advancements in Q3 2023 (GuruFocus.com)
08:00AM	TriSalus Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Nov-07-23 04:05PM	TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call (Business Wire) -5.39%
Nov-04-23 02:25PM	Late-Breaking Phase 1 Liver Metastasis Data from TriSalus Presented at SITC 2023 Supports Development of Innovative Immuno-oncology Approach for Liver and Pancreas Indications (Business Wire)
Nov-03-23 12:00PM	TriSalus Life Sciences Presents Data for SD-101 Delivered by TriSalus Infusion System for Pancreatic Adenocarcinoma at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (Business Wire) +12.90%
Oct-25-23 09:05AM	TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (Business Wire)
Sep-06-23 07:00AM	TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics (Business Wire) -6.96%
Aug-10-23 04:05PM	TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation (Business Wire) +18.67%
Aug-02-23 05:00PM	MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders (Business Wire) -5.60%
Jun-12-23 07:00AM	TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD Method with the TriNav Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting (Business Wire)
Apr-20-23 07:00AM	TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD Method in Stage IV Uveal Melanoma Patients With Liver Metastases (Business Wire)
Feb-21-23 07:00AM	TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business (Business Wire)
Dec-07-22 09:26PM	MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders (GlobeNewswire)
Nov-14-22 04:24PM	Colorado biotech company to go public via SPAC merger (American City Business Journals)
02:32PM	Loading…
Mar-14-22 02:32PM	Robotic surgery company Memic pulls out of SPAC merger (American City Business Journals)
Mar-10-22 08:11AM	MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination (GlobeNewswire)
Jan-06-22 08:00AM	Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021 (PR Newswire)
Dec-30-21 03:00PM	A look at the South Florida tech companies that were acquired or went public in 2021 (American City Business Journals)
Oct-07-21 09:16AM	Is MedTech Acquisition Corporation (NASDAQ:MTAC) Popular Amongst Institutions? (Simply Wall St.)
Sep-09-21 06:00AM	Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition Corporation (PR Newswire)
Sep-03-21 09:25AM	Moore Kuehn Encourages FRSG, MTAC, SLCR, and ADF Investors to Contact Law Firm (GlobeNewswire)
Aug-19-21 12:32PM	Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal (PR Newswire)
Aug-13-21 05:49PM	SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of MedTech Acquisition Corporation (Nasdaq - MTAC) (ACCESSWIRE)
08:07AM	Memic Innovative Surgery Ltd. and MedTech Acquisition Corporation Announce Proposed Business Combination (PR Newswire)
Jun-02-21 04:05PM	MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-19-21 01:02PM	Robotics Firm Memic Is in Talks to Go Public Via SPAC (Bloomberg)

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLSI

TriSalus Life Sciences Inc

Upgrade your FINVIZ experience